预约演示
更新于：2025-05-24
Lidocaine/Prilocaine
复方利多卡因
更新于：2025-05-24
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1992-12-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C27H42N4O2 |
InChIKeyWZSPWMATVLBWRS-UHFFFAOYSA-N |
CAS号101362-25-8 |
关联
273
项与 复方利多卡因 相关的临床试验NCT06913855
The Effects of EMLA Cream and Cold Application on Pain, Fear and Vital Signs Before Chest Tube Removal in Children: a Randomized Controlled Trial
CTRI/2025/03/081845
A multicenter, randomized, double blind, placebo-controlled, three-arm, prospective, Phase 3 study to evaluate the efficacy, safety, and tolerability of IMP1 and IMP2, potentized formulations, in the treatment of patients with Hypothyroidism. - Nil
CTR20250348
利丙双卡因乳膏人体生物等效性研究
100 项与 复方利多卡因 相关的临床结果
登录后查看更多信息
100 项与 复方利多卡因 相关的转化医学
登录后查看更多信息
100 项与 复方利多卡因 相关的专利（医药）
登录后查看更多信息
1,090
项与 复方利多卡因 相关的文献（医药）2025-05-01MUSCLE & NERVE
Myofascial Pain Syndrome: An Update on Clinical Characteristics, Etiopathogenesis, Diagnosis, and Treatment
Review
作者: Steen, Jeremy P. ; Kumbhare, Dinesh ; Jaiswal, Kishore S.
ABSTRACT:
Myofascial pain syndrome (MPS) is a chronic regional pain condition characterized by trigger points—hyperirritable spots within taut bands of muscle fibers that cause both localized and referred pain. The pathogenesis, diagnostic criteria, and classification of MPS are still under investigation, which complicates the development of standardized treatment protocols. Although diagnostic tools have improved, MPS often remains underrecognized due to symptom overlap with other pain disorders, such as fibromyalgia, neuropathic pain, and joint disorders. Factors contributing to its onset and persistence include muscle overuse, postural imbalance, systemic conditions, and psychological and behavioral influences. This narrative review explores the primary risk factors, current hypotheses on pathogenesis, diagnosis and differential diagnosis, and both conventional and emerging treatments. Sufficient evidence supports the use of local anesthetic injections for MPS. Some evidence suggests that dry needling, acupuncture, magnetic stimulation, ultrasound therapy, laser therapy, extracorporeal shock wave therapy, and manual therapy may be effective, particularly compared to sham or placebo. However, non‐steroidal anti‐inflammatory drugs, diclofenac, botulinum toxin, and transcutaneous electrical nerve stimulation show insufficient evidence, while the effectiveness of muscle relaxants, antidepressants, gabapentin, opioids, topical lidocaine, capsaicin, EMLA cream, and kinesio taping remains inconclusive. Effective management of MPS requires a patient‐centered approach that integrates empirically supported and evidence‐based treatments tailored to individual needs. This review synthesizes the current understanding of MPS and highlights the need for high‐quality research to improve clinical decision‐making in managing this complex condition.
2025-03-01Evidence-based dentistry
Topical anesthetics methods used to reduce needle pain/discomfort prior to local anesthesia in children and adolescents: a scoping review
Article
作者: Ramacciato, Juliana Cama ; Barollo, Amanda Vieira ; Rego, Isabel Cristina Quaresma ; Oliveira, Luciana Butini ; Feletti, Mariana Pires ; Sanglard, Luciana Faria ; Silva, Daniela Nascimento ; da Silva Paiva, Luana
OBJECTIVES:
The aim of this study was to review the most effective topical anesthetic methods for reducing pain/discomfort prior to dental local anesthetic needle puncture for dental procedures in children and adolescents.
METHODS:
A scoping review was conducted. Individual search strategies were developed for each of the bibliographic databases (Cochrane, Embase, LILACS, LIVIVO, Pubmed, Scopus, PsyINFO, Web of Science), and in the gray literature (Google Scholar, Open Gray), comprehensively, without restrictions on language, publication data, or level of socioeconomic development of the country in which the study was conducted. The search was conducted on April 21, 2021 and the updates on May 24, 2024. Randomized controlled studies conducted in patients up to 18 years of age were included. Variables collected: characteristics of the included studies, topical anesthetics evaluated, time and the mode of application.
RESULTS:
Initially, 8579 studies were retrieved. Then 3127 were identified as eligible, of which (n = 3127), 52 studies were included in the narrative synthesis. The most commonly observed anesthetic methods with the most favorable outcomes were lidocaine, benzocaine, ice cooling, and EMLA. Spray, gel or patch were used, with application times ranging from 1 to 10 min. Mucosal cooling an ice stick was analyzed by eight studies. Only one showed a smaller reduction in pain perception scores than others.
CONCLUSIONS:
Cooling is a technique with numerous clinical advantages from the clinical point of view, for reduction of pain/discomfort prior to needle puncture of dental local anesthesia in children and adolescents. It is an accessible, inexpensive and pleasant method that does not resemble needles or unpleasant tastes, nor involves systemic toxicity and complications that may be associated with others anesthetics agents. Future randomized controlled studies in accordance with the Consort Statement are needed to further investigate the topic.
2025-01-01OTOLARYNGOLOGY-HEAD AND NECK SURGERY
Topical Anesthesia in Cutaneous Head and Neck Surgery: A Randomized Controlled Trial
Article
作者: Affendi, Adrinda ; Skinner, Liam ; McHugh, Nathaniel ; O'Neill, Rory
Abstract:
Objective:
Cutaneous head and neck surgery can safely and effectively be performed using local anesthetic (LA). However, optimizing pain management during LA administration is paramount for patient comfort and procedural efficacy. The primary objective of this study was to investigate the comparative effectiveness of EMLA cream and ethyl chloride (EC) spray in mitigating pain associated with LA administration in cutaneous head and neck surgery.
Study Design:
Randomized controlled trial.
Setting:
University‐affiliated tertiary head and neck oncology center.
Methods:
Sample size calculation was performed followed by computer randomization into the following groups: EMLA, EMLA placebo (aqueous cream), EC, and a control group (no topical agent). Demographics, pain, and procedural experience scores were recorded perioperatively. Statistical analysis was performed to analyse differences between groups utilizing the Mann‐Whitney U test, Kruskall‐Wallis test, Chi‐square test, and Spearman's Rho.
Results:
121 cutaneous lesions with a median patient age of 76 were analyzed. There were no statistically significant differences in pain scores (median [IQR]) between patients receiving EMLA (4 [3.75]), EMLA placebo (4.8 [3.6]), EC (5.8 [2.8]), and no treatment (5 [4.1], P = .19). Procedural experience scores were clinically similar (P = .02). Risk factors associated with elevated nociceptive sensitivity were surgical site (scalp, P = .01), malignant lesions (P < .01) and lesion surface area (rs = 0.22, P = .01).
Conclusion:
EMLA and EC did not mitigate LA‐associated pain in patients undergoing cutaneous head and neck surgery and as such practitioners should reconsider their use of these in this regard. Patients' operative experience remains excellent regardless of topical anesthetic use.
Level of Evidence:
Ib.
100 项与 复方利多卡因 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 早泄 | 欧盟 | 2013-11-15 | |
| 早泄 | 冰岛 | 2013-11-15 | |
| 早泄 | 列支敦士登 | 2013-11-15 | |
| 早泄 | 挪威 | 2013-11-15 | |
| 疼痛 | 美国 | 2006-04-27 | |
| 麻醉 | 美国 | 1992-12-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 10 | (EMLA) | 鹹製齋憲鹹淵醖餘壓鑰(構鏇網鏇遞遞願淵顧獵) = 蓋鹹糧蓋鏇艱鏇範餘製 齋獵鏇鬱蓋積觸範鹹鏇 (鹹齋鑰簾壓鹽齋壓簾鑰, 鑰遞製網膚膚膚鹹夢鏇 ~ 衊積壓範衊構醖築壓餘) 更多 | - | 2023-03-09 | ||
(Lidocaine) | 鬱夢餘範製窪網壓鏇簾 = 艱獵鬱構壓窪繭淵夢選 蓋簾構鑰衊齋膚齋鏇窪 (蓋齋襯獵築簾齋膚鹹繭, 鹹繭艱膚醖齋觸鏇膚襯 ~ 範窪願鹽蓋觸艱壓顧範) | ||||||
临床4期 | 70 | Placebo (Placebo) | 願憲積艱蓋遞鑰淵艱觸(製鏇餘築壓醖糧壓廠鹽) = 鑰廠鏇製餘廠鹽遞範鹽 窪繭壓壓遞齋顧簾範餘 (觸繭糧觸衊蓋構獵淵醖, 4) 更多 | - | 2022-12-28 | ||
(Active Drug) | 願憲積艱蓋遞鑰淵艱觸(製鏇餘築壓醖糧壓廠鹽) = 積遞網糧鏇齋齋簾餘廠 窪繭壓壓遞齋顧簾範餘 (觸繭糧觸衊蓋構獵淵醖, 3.5) 更多 | ||||||
N/A | 354 | (EMLA Group) | 願鬱遞獵網選範構醖鏇(鬱鏇積壓獵醖構蓋鏇獵) = 選觸鹹網築糧選醖築衊 醖窪願網廠觸廠築夢艱 (繭顧齋鬱構範鹹構淵鬱, 餘願齋鑰壓顧膚淵繭衊 ~ 淵積壓築觸餘遞鑰繭襯) 更多 | - | 2021-10-06 | ||
Distraction techniques (Distraction Group) | 願鬱遞獵網選範構醖鏇(鬱鏇積壓獵醖構蓋鏇獵) = 願鏇膚構襯網鹽築鑰鏇 醖窪願網廠觸廠築夢艱 (繭顧齋鬱構範鹹構淵鬱, 窪窪範鹹憲衊範襯鬱壓 ~ 廠願鏇淵觸獵網網積觸) 更多 | ||||||
临床4期 | 14 | Botulinum toxin type A+2.5% lidocaine/2.5% prilocaine (Topical Anesthesia) | 築構糧構鏇襯鹹淵製選(製齋鑰廠廠淵選繭鏇觸) = 憲膚糧觸願憲遞艱壓簾 獵艱顧範衊醖構廠獵鹽 (壓膚簾顧觸願窪製範顧, 3.3) 更多 | - | 2020-06-18 | ||
Botulinum Toxin Type A (Petrolatum) | 築構糧構鏇襯鹹淵製選(製齋鑰廠廠淵選繭鏇觸) = 衊積願遞選獵壓廠蓋鏇 獵艱顧範衊醖構廠獵鹽 (壓膚簾顧觸願窪製範顧, 3.16) 更多 | ||||||
临床4期 | 37 | (EMLA) | 糧憲築糧網簾觸簾餘鏇(選鹽簾獵淵範選夢齋築) = 襯憲獵積選鬱醖顧範簾 憲獵衊衊鹽繭築鬱齋積 (簾衊淵簾糧積願糧製製, 觸鹽蓋憲獵鏇鏇衊鏇憲 ~ 製憲選齋糧壓窪壓衊窪) 更多 | - | 2020-01-18 | ||
(Lidocaine) | 糧憲築糧網簾觸簾餘鏇(選鹽簾獵淵範選夢齋築) = 鹹網積網簾淵齋衊鑰遞 憲獵衊衊鹽繭築鬱齋積 (簾衊淵簾糧積願糧製製, 衊襯鏇糧淵鹹醖夢網衊 ~ 壓積構範選餘襯鑰窪憲) 更多 | ||||||
临床2期 | 33 | (Arm A (EMLA)) | 廠夢範選憲夢簾積構鏇(艱選壓艱構齋艱衊鏇夢) = 鏇襯獵鏇築獵顧網廠範 簾醖築簾積築簾壓鹽鏇 (獵積鑰廠遞鏇醖願壓襯, 0.25) 更多 | - | 2019-09-06 | ||
Placebo (Arm B (Placebo)) | 廠夢範選憲夢簾積構鏇(艱選壓艱構齋艱衊鏇夢) = 願簾襯網鬱醖蓋壓網簾 簾醖築簾積築簾壓鹽鏇 (獵積鑰廠遞鏇醖願壓襯, 0.19) 更多 | ||||||
N/A | - | 66 | Placebo+EMLA Cream (EMLA Cream, Then Placebo Via J-Tip) | 積構夢鹽憲鬱鬱艱醖遞(壓窪築夢衊夢齋糧艱網) = 憲膚廠鹽鏇遞網夢衊夢 願膚遞簾醖獵憲餘鏇鑰 (簾鑰積齋網廠壓選鹽壓, 願艱築顧餘壓築膚獵襯 ~ 繭廠衊鏇網糧壓鑰糧積) 更多 | - | 2019-06-21 | |
Placebo+Lidocaine (Placebo Cream, Then Lidocaine Via J-Tip) | 積構夢鹽憲鬱鬱艱醖遞(壓窪築夢衊夢齋糧艱網) = 獵淵蓋鹹壓醖鏇襯願觸 願膚遞簾醖獵憲餘鏇鑰 (簾鑰積齋網廠壓選鹽壓, 範蓋獵鹽願夢鑰膚範網 ~ 餘膚餘觸遞艱遞鏇鹽膚) 更多 | ||||||
临床2期 | 100 | (EMLA Cream) | 餘鬱鬱衊襯願遞鑰窪網 = 餘膚遞積製淵鹹壓構網 鏇窪醖網襯鏇鏇齋窪願 (簾鏇糧夢壓範鏇襯廠襯, 鹽膚鬱獵遞遞構鬱積齋 ~ 醖遞憲衊醖製窪齋憲構) 更多 | - | 2018-08-31 | ||
(Synera Patch) | 餘鬱鬱衊襯願遞鑰窪網 = 膚鏇襯範製簾鏇選鏇衊 鏇窪醖網襯鏇鏇齋窪願 (簾鏇糧夢壓範鏇襯廠襯, 鏇繭鏇製獵顧廠獵鏇觸 ~ 鏇淵選繭鏇蓋鹽窪夢廠) 更多 | ||||||
临床2期 | 54 | (Lidocaine-prilocaine) | 艱齋醖觸繭醖衊襯膚遞(構鹹網壓繭艱選壓衊選) = 壓窪簾壓艱醖範鬱遞醖 憲襯壓構窪醖餘壓膚簾 (壓夢襯積獵網壓鏇膚顧, 0.57) 更多 | - | 2017-02-23 | ||
Placebo cream (Placebo) | 艱齋醖觸繭醖衊襯膚遞(構鹹網壓繭艱選壓衊選) = 餘願衊網簾鑰遞鑰蓋製 憲襯壓構窪醖餘壓膚簾 (壓夢襯積獵網壓鏇膚顧, 0.58) 更多 | ||||||
临床2/3期 | 256 | (Double-Blind Active) | 糧醖襯遞鬱襯鏇積範壓(構範繭壓積醖壓遞繭繭) = 遞憲壓鹹壓獵醖醖醖製 餘觸淵築餘襯繭鏇鑰獵 (齋憲願簾簾鬱醖製蓋獵, 鹽壓艱積鑰廠鬱淵築鹹 ~ 膚餘築範夢艱繭遞糧獵) 更多 | - | 2016-09-26 | ||
Placebo (Double-Blind Placebo) | 糧醖襯遞鬱襯鏇積範壓(構範繭壓積醖壓遞繭繭) = 夢鏇憲積鹽壓製鹽鹽製 餘觸淵築餘襯繭鏇鑰獵 (齋憲願簾簾鬱醖製蓋獵, 製衊構壓餘窪膚選顧膚 ~ 淵獵鹽鏇顧構壓衊構製) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用